Get the Stockscreener App
9.815
1.82%
0.175
Pharming Group Nv Adr stock is traded at $9.815, with a volume of 2,693.
It is up +1.82% in the last 24 hours and down -6.97% over the past month.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
See More
Previous Close:
$9.64
Open:
$9.5
24h Volume:
2,693
Relative Volume:
0.28
Market Cap:
$694.69M
Revenue:
$370.44M
Net Income/Loss:
$12.19M
P/E Ratio:
56.96
EPS:
0.1723
Net Cash Flow:
$50.74M
1W Performance:
+2.99%
1M Performance:
-6.97%
6M Performance:
-44.86%
1Y Performance:
-31.72%
1-Day Range:
$9.50
$10.03
1-Week Range:
$9.32
$9.90
52-Week Range:
$9.32
$21.34
Pharming Group Nv Adr Stock (PHAR) Company Profile
Compare PHAR vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHAR
Pharming Group Nv Adr
|
9.815 | 694.69M | 370.44M | 12.19M | 50.74M | 0.1723 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.11 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.35 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Pharming Group Nv Adr Stock (PHAR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Canaccord Genuity | Buy |
| Dec-09-24 | Initiated | Jefferies | Buy |
Pharming Group Nv Adr Stock (PHAR) Latest News
Zai Lab LimitedADR Peer Comparison – Compare with Others - valueresearchonline.com
PHAR Q2 2026 Earnings: EPS Falls 90% Short of ConsensusAnalyst Drop Coverage - careplusvn.com
PHAR Q2 2026 Earnings: EPS Falls 90% Short of ConsensusEarnings Season Preview - dars.gov.et
PHAR Q2 2026 Earnings: EPS Falls 90% Short of ConsensusBalance Sheet Strength - dars.gov.et
Pharming Group (PHAR) Slips 3.22% to $11.11: Key Support Zone in FocusHagopian Line - careplusvn.com
Pharming Group (PHAR) Slips 3.22% to $11.11: Key Support Zone in FocusDescending Triangle - dars.gov.et
Pharming Group (PHAR) Slips 3.22% to $11.11: Key Support Zone in FocusOversold Bounce Ideas - dars.gov.et
XORTX Therapeutics Inc. (XRTX) Peer Comparison – Compare with Others - Value Research
Pharming (PHAR) Quarterly Results: The EPS Result Is Below Expectation in the Latest Session; Investor Response: Shares Move Lower 0.30% in the Current UpdateSlow Growth Warning - dars.gov.et
Pharming (PHAR) EPS and Revenue: The Bottom-Line Figure Trails Its Comparison under the Current Snapshot; After Earnings: The Market Price Declines 1.43% on the DayEarnings Preview - dars.gov.et
Pharming (PHAR) EPS and Revenue: The Bottom-Line Figure Trails Its Comparison under the Current Snapshot; After Earnings: The Market Price Declines 1.43% on the DayMargin Expansion Trends - dars.gov.et
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Up 93.0% in July - MarketBeat
Pharming Group (PHAR) Slides 5.1% to $11.72 as Rare-Disease Biotech Faces Selling PressureTrading Ideas - careplusvn.com
Pharming Group (PHAR) Slides 5.1% to $11.72 as Rare-Disease Biotech Faces Selling PressureInsider Selling Alerts - dars.gov.et
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Hold" by Brokerages - MarketBeat
Pharming Group (NASDAQ:PHAR) Shares Gap DownShould You Sell? - MarketBeat
Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Pharming (PHAR) Q2 2026 Earnings: 90% EPS Miss Overshadowed by Resilient Share PriceRevenue Warning Signal - careplusvn.com
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pharming Grou - The National Law Review
Pharming Group (PHAR) Securities Investigation NoticeLevi & Korsinsky - Sahm
Pharming Group (NASDAQ:PHAR) Shares Gap UpTime to Buy? - MarketBeat
Pharming Group (PHAR) Advances 1.93% to $10.01, Approaches Key Resistance at $10.51IV Spike - careplusvn.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Q3 EPS Estimates for Pharming Group Lowered by HC Wainwright - MarketBeat
PHAR Q2 2026 Earnings: Marginal EPS Miss Triggers 15.5% SelloffCFO Commentary Report - careplusvn.com
Pharming Group (NASDAQ:PHAR) Shares Gap Down Following Weak Earnings - MarketBeat
PHAR Q2 2026 Earnings: Marginal EPS Miss Triggers 15.5% SelloffSurprise Factor Analysis - dars.gov.et
PHAR Q2 2026 Earnings: Marginal EPS Miss Triggers 15.5% SelloffEarnings Surprise Score - https://www.dars.gov.et/
Pharming Q2 2026 slides: Joenja growth offsets RUCONEST pressure - investing.com
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update - MarketBeat
Pharming Group NV Sponsored ADR Revenue Breakdown – DUS:PHG - TradingView
Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Hold" by Analysts - MarketBeat
Pharming Group (NASDAQ:PHAR) Shares Gap DownHere's What Happened - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Pharming Group N.V - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Pharming Group N.V - The National Law Review
A2QLQY Forecast — Price Target — Prediction for 2027 - TradingView
Pharming Group NV Sponsored ADR Actuals & Estimates (NASDAQ:PHAR) - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
A2QLQY Forecast — Price Target — Prediction for 2027 - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
PHG Forecast — Price Target — Prediction for 2027 - TradingView
DBV Technologies (DBVT) soars 5.3%: Is further upside left in the stock? - MSN
DBV Technologies (DBVT) soars 5.3%: Is further upside left in the stock? - MSN
DBV Technologies (DBVT) soars 5.3%: Is further upside left in the stock? - MSN
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Form 6K Pharming Group NV For: 28 May By Investing.com - Investing.com South Africa
Pharming Group Nv Adr Stock (PHAR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.62%
2.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):